Navigation Links
InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
Date:2/17/2010

ermune.com">www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.  Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon these data, in combination with the other efficacy and safety results the company has submitted in support of its NDA filing and currently intends to submit in support of its MAA filing.

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" attached as Exhibit 99.3 to InterMune's Form 8-K filed with the SEC on January 20, 2010, and other periodic reports filed with the SEC, including the following: (i) the fact that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, have declined significantly following the March 2007 termination of the Phase 3 INSPIRE trial
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... SANTA ROSA, Calif. , Oct. 24, 2014 /PRNewswire-USNewswire/ ... he was ordering large quantities of multiple controlled substances, ... patient care. They also reported that Dr. Gurney was ... Medical Board reported that one of his employees said ... his care and treatment of patients." Dr. ...
(Date:10/25/2014)... , October 24, 2014 ... ) has announced the addition of the  ... 2014"  report to their offering.  ... and Chinese Acne Medication Industry Report 2014 ... the current state of the global acne ...
(Date:10/25/2014)... Oct. 24, 2014  As the building blocks ... company access to diverse skill sets and expertise, ... clock business hours for efficiency. However, effectively managing ... According to recent research, more than ... seeing a project not move forward due to ...
Breaking Medicine Technology:Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 2Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 3Global and Chinese Acne Medication Industry Report 2014 2Global and Chinese Acne Medication Industry Report 2014 3Work Around the Clock: Successfully Building & Managing Global Virtual Teams 2
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. ... cold sores -- herpes simplex -- might increase the risk ... In fact, being a carrier of certain antibodies to the ... found. "The identification of a treatable cause [herpes ... said lead researcher Dr. Hugo Lovheim, an associate professor in ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Researchers who ... their findings are cause for concern. The ... are raised for human consumption contribute to the ... according to background information from the study. ... sicken about 2 million people and kill about ...
(Date:10/25/2014)... FRIDAY, Oct. 23, 2014 (HealthDay News) -- Current ... many younger postmenopausal women at risk for osteoporosis-related ... want to prevent fractures, we need tools that ... osteoporotic injuries so that we can target these ... Carolyn Crandall, professor of medicine in the division ...
(Date:10/25/2014)... 2014 (HealthDay News) -- October,s shorter, darker days can ... disorder, according to an expert. People affected ... overly tired, lack motivation and even have trouble getting ... to suicide, said Dr. Angelos Halaris, a professor in ... University Chicago Stitch School of Medicine. "Seasonal affective ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 On Saturday, October ... its fourth annual family health and fitness fair ¡Vive tu ... physical activity and good nutrition for better health and wellness ... which is free and open to the public, will be ... Brownsville, from 9:00 am to 1:00 pm. , “¡Vive ...
Breaking Medicine News(10 mins):Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4
... (“bad” cholesterol) to below 100 milligrams per deciliter by ... safe and results in fewer cardiovascular events. ,The ... 10 milligrams of atorvastatin (Lipitor) a day to get ... a day or lower. Then, half of the patients ...
... have been conducted to see whether antihypertensive strategies ... // are superior to older treatments with beta-blockers ... calcium channel blocker amlodipine with or without the ... or without the diuretic bendroflumethiazide. ,The trial ...
... stem cell research that will help in numerous therapies using ... growing human embryonic stem cells in the laboratory. ... important role in regeneration of cells for therapeutic use. However, ... live animal cells and serum and run the risk of ...
... Medical Association, researchers have pointed out that there seems to ... the children resulting in increase in risk of the vaccinated ... study, most of the vaccines that need to be completed ... gets delayed due to a variety of reasons, most important ...
... cases of testicular cancer occur and it is the most ... than 90 percent of the cases can be cured, especially ... difficult to detect the cancer before it starts to spread. ... detecting testicular cancer before it spreads. ,Researchers say they ...
... ,Researchers led by Professor Julie Williams and Professor Michael O'Donovan ... to be the cause of dyslexia in children. An analysis ... from dyslexia was done to identify the gene. The gene ... breakthrough and the first study to identify one gene which ...
Cached Medicine News:
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: